Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for the ...
In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...
The Muscular Dystrophy Association (MDA) is proud to announce the recipients of the 2026 MDA Legacy Awards, recognizing excellence in scientific and clinical research and saluting outstanding ...
Shares of Regenxbio rose Monday in premarket trading after the company said its treatment for Duchenne muscular dystrophy delivered positive trial results, strengthening the case for a speedier ...
Solid Biosciences (SLDB) stock rises as a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy reaches ...
PPMD extends its heartfelt thanks to all Race to End Duchenne runners, donors, and volunteers who made the 2026 Walt Disney World (R) Marathon Weekend a memorable and meaningful success. To learn more ...
The U.S. Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a certain ...
Muscle tissue damage appears when muscular dystrophy is induced in a mouse model (middle). But when researchers block the function of two genes that drive unwanted mitochondrial pore formation (right) ...
Coming shortly off the success of its efforts during National Muscular Dystrophy Awareness Month, the Muscular Dystrophy Association (MDA) is helming another fundraising push. From November to January ...
Leah Messer is opening up about navigating her daughter Ali's muscular dystrophy as the 15-year-old takes a big step in her life: high school. In an interview with TooFab ahead of the new season of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback